https://www.businesswire.com/news/home/20260611674142/en/ABL-Diagnostics-and-CDL-Pharma-Secure-a-Multi-year-International-Contract-of-up-to-%E2%82%AC2.7-Million-Through-2031
https://www.einpresswire.com/article/912523931/abl-diagnostics-announces-strategic-ai-roadmap-to-advance-molecular-research-and-global-data-security
Julia Faillace Thiesen , Elise Jacquemet , Pascal Campagne, Denis Chatelain, Etienne Brochot, Yves‑Edouard Herpe , Nolwenn M. Dheilly , Fabrice Bouilloux, Bénédicte Rognon, Alexandre Douablin, Guillaume Leboucher , Florent Percher, Marc Eloit and Philippe Pérot Abstract Background Cervical cancer screening programs are increasingly relying on sensitive molecular approaches as primary tests to detect high‑risk
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the release of its DeepChek®-HPV Assay for the screening, the genotyping, and the discrimination of the Human Papillomavirus (“HPV”). The assay uses an innovative design which allows
Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce a major evolution of its research & development activities with the design of CRISPRChek, a new line of molecular assays using the disruptive CRISPR technology. With the intent
ABL Diagnostics increases its production capacities and its resilience thanks to the “France Relance” program ABL Diagnostics is pleased to announce that a substantial increase of its molecular assays production capacities has been allowed thanks to the RESILIENCE France Relance program entitled “SOUTIEN A L’INVESTISSEMENT ET LA MODERNISATION DE L’INDUSTRIE“. In the context of the
ABL Diagnostics signed a Channel Partner Agreement with Illumina to offer, combined with ABL Diagnostics’ DeepChek™ products, on the iSeq™ 100 and MiSeq™ next-generation sequencing platforms to microbiology laboratories in mainland France Belgium and Luxembourg ABL Diagnostics is pleased to announce a strategic collaboration with Illumina through an international Channel Partners Agreement conferring to ABL
ABL Diagnostics signed a Channel Partners Agreement with Illumina Read More »
Atout Capital a conseillé ABL Diagnostics pour la fusion-absorption de l’activité diagnostic médical d’ABL France à hauteur de 28 m€ ABL DIAGNOSTICS développe, fabrique et commercialise des kits de tests de diagnostic par détection moléculaire et de tests de génotypage par séquençage d’ADN, ciblant des maladies infectieuses chroniques. ABL DIAGNOSTICS a ainsi développé des produits
Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA On September 1st 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL Diagnostics SA (ABLD), a worldwide leading international company, listed on Euronext Paris compartment C (ISIN FR001400AHX6), offering innovative and proprietary molecular biology assays and end-to-end
